Loading...
Update on the role of brentuximab vedotin in classical Hodgkin lymphoma
Brentuximab vedotin (BV) is an effective and well-tolerated treatment for patients with classical Hodgkin lymphoma (HL). It was initially approved by the US FDA for the treatment of HL after failure of autologous hematopoietic stem cell transplant (autoHSCT) or after failure of at least two prior li...
Saved in:
| Published in: | Ther Adv Hematol |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
SAGE Publications
2018
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6130098/ https://ncbi.nlm.nih.gov/pubmed/30210755 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620718786833 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|